Precision AQ - Investor Relations & External Communications’ Post

Calling all #lupus specialists & researchers: The March edition of our Literature Highlights & detailed slide decks are now available on the Lupus-Forum, featuring key advancements in lupus research and therapeutics. This month, we delve into topics such as the efficacy of #CAR-T cell therapy, the role of #belimumab in treating childhood-onset #SLE, and the latest in #SLE diagnosis: https://lnkd.in/euBZmUb7

For cell therapies, the path to the clinic is marked by critical scientific and regulatory milestones that require careful planning, expertise, and collaboration. On March 7, join Premier Research and BioCentriq as we discuss the intricacies of early cell therapy development that shape the path toward clinical trials. Mark you calendars: https://bit.ly/3UlHBk5

Today marks an important milestone for Cartesian as we share positive topline results from our Phase 2b trial of Descartes-08 in patients with #myastheniagravis. Descartes-08 is the first mRNA cell therapy designed to treat MG. Learn more about the results and next steps as we continue our journey to treat #autoimmunediseases: https://bit.ly/3xJjvXA

This article, authored by Dr. Bruce L. Levine and a team of scientists, delves into the FDA's investigation on T cell malignancies post-CAR-T cell therapy, emphasizing the need for long-term monitoring and investigating potential causal links. The article highlights the importance of investigating potential causal links between CAR-T therapy and T cell malignancy, providing insights into reported cases and comparing risks with other treatments. The authors recommend continued use of CAR-T therapies, pending FDA results, and stress the importance of adherence to safety studies and prompt reporting of subsequent malignancies. https://lnkd.in/euHw852a

📰 Are more rapid sterility testing methods needed? According to a group of researchers at SCTbio, the answer is yes. In this week's #cellandgene newsletter, we learn more about a neglected area of #CAR-T optimization. We also explore AstraZeneca's recent $300 million facility investment in Maryland. And, research from California State University, Los Angeles - College of Professional and Global Education that has identified Tyrosinase Related Protein 1 as a CAR-T cell therapy target to treat patients with cutaneous and rare melanoma subtypes. 🔎 Not subscribed to our newsletter yet? Sign up here: https://bit.ly/3SCDpKo

Biotech communications professionals often use terms like paradigm shifting, best-in-class, novel, etc. I’m guilty of it too. But the topline results presented today are more than just a subjective interpretation of data. Despite a relatively small study, the MG patients that responded to Descartes-08 did so with disease modifying results. This treatment didn’t just manage their symptoms – it altered how they were able to live.   Proud to be part of Cartesian Therapeutics, looking forward to advancing Descartes-08 for #myastheniagravis to a phase 3 trial, and seeing the future potential of our platform for #autoimmunity.

🗣️ Cellistic recently hosted a webinar as part of the Cell&Gene program at the Outsourced Pharma Capacity virtual event. We discussed some of the main challenges of allogeneic cell therapy: ❓How to manufacture allogeneic treatments to accelerate their delivery to patients? ❓What are the obstacles? ❓How can new cell therapy technologies address them? Watch the #webinar recording here to gain some insights from #expert Stefan Braam about those questions & do not hesitate to reach out for a discussion! #Cellistic #AllogeneicCellTherapy #iPSCs

How can manufacturers develop workflows to deliver highly individualized cell therapy products while developing processes that can deliver scalable treatments? Master tumor infiltrating lymphocyte therapy manufacturing with this recourse from Cytiva. Download now >>> https://hubs.ly/Q02pMpdk0

Next step for CAR T cell therapy: in vivo CART from @ASGCT24 Interius Biotherapeutics will release preclinical study of INT2104 (CAR20) in humanized NSG-Tg (Hu-IL15) and Cyno. INT2104 utilizes a lentiviral vector platform that incorporates CD7-targeting to specifically transduce T cells and NK cells upon intravenous (i.v.) administration.

Calling all #lupus specialists & researchers: The April edition of our Literature Highlights & detailed slide decks are now available on the Lupus-Forum, featuring key advancements in lupus research and therapeutics. This month, we delve into topics such as the safety and efficacy of CD19 #CAR-T cell therapy, the role of #anifrolumab in treating #SLE, the establishment of autoantigen-specific Treg-cell-based therapy in #LN, and the latest on cardiovascular risk factors in #SLE patients: https://lnkd.in/dCk9aBNk